

# A Facile Preparation of 7-(Substituted amino)-6*H*-pyrrolo[3,4-*d*]-pyrimidine Derivatives<sup>1)</sup>

Michihiko NOGUCHI,\* Yasutoshi KIRIKI, and Shoji KAJIGAESHI

Department of Industrial Chemistry, Faculty of Engineering, Yamaguchi University, Tokiwadai, Ube 755

(Received May 15, 1989)

**Synopsis.** 6-Phenyl-7-(substituted amino)-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-diones **3** were obtained by the reaction of 5-formyl-1,3-dimethyl-6-[(substituted amino)methyl]-2,4(1*H*,3*H*)-pyrimidinediones (**1**) with aniline (**2a**).

Recently, we reported a one-pot preparation of 6,7-dihydropyrrodo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione derivatives (**D**) from the reaction of 5-formyl-1,3,6-trimethyl-2,4(1*H*,3*H*)-pyrimidinedione (**A**) with primary amines.<sup>2)</sup> The cycloaddition reaction of 5,6-dihydro-5,6-bis(methylene)-2,4(1*H*,3*H*)-pyrimidinedione **B**, generated via 1,5-hydrogen shift of **A**, and aldimines from **A** and amines yielding 5,6,7,8-tetrahydropyrrodo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione **C** was the key step in this pyridopyrimidine synthesis.

In the continuation of the investigations on the preparation of fused pyrimidines, we wish to describe here a facile preparation of 7-(substituted amino)-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione derivatives from the reaction of 5-formyl-1,3-dimethyl-6-[(substituted amino)methyl]-2,4(1*H*,3*H*)-pyrimidinedione with primary amines.

## Results and Discussion

The reaction of 5-formyl-1,3-dimethyl-6-(morpholinomethyl)-2,4(1*H*,3*H*)-pyrimidinedione (**1a**) with aniline (**2a**) in benzene under reflux afforded 1,3-dimethyl-7-morpholino-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**3a**) in 59% yield. The reaction of other 5-formyl-6-[(substituted amino)methyl]-2,4(1*H*,3*H*)-pyrimidinediones (**1**) with aniline (**2a**) was also examined. The reaction patterns depended on the kind of the substituted amino groups; the reaction of 6-[(1-pyrrolidinyl)methyl]- (**1b**) afford-


ed only **3b**, the same type product as **3a**, while the reaction of 6-[(diethylamino)methyl]- (**1c**) and 6-[(*N*-methylanilino)methyl]- (**1d**) afforded 1,3-dimethyl-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**4**)<sup>3)</sup> as a major product together with the corresponding 7-(substituted amino) derivatives **3c** and **3d**, respectively.

The structural elucidation of pyrrolopyrimidines **3** was accomplished on the basis of their spectral data comparing with those of **4**.

A pathway for these pyrrolopyrimidines **3** and **4** can be explained by the analogy to that for pyrido[3,4-*d*]pyrimidines **C** from **A** and primary amines. The 1,5-hydrogen shift of the aldimine **E** from **1** and aniline (**2a**) affords a 5-anilinomethylene-5,6-dihydro-6-[(substituted amino)methylene]-2,4(1*H*,3*H*)-pyrimidinedione intermediate (**F**). The 1,5-cyclization of **F** leads to a 6,7-dihydro-5*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**G**). The dehydrogenation of **G** gives the 7-(substituted amino) derivatives **3**, while the deamination of **G** gives pyrrolopyrimidine **4**.

The above pathway for the formation of **G** is related to that for 6-tosylamino-6*H*-pyrrolo[3,4-*d*]pyrimidine synthesis by the reaction of 1,2,3,4-tetrahydro-6-bromomethyl-1,3-dimethyl-2,4-dioxo-5-pyrimidinecarbaldehyde tosylhydrazone with triethylamine, in which the 1,5-cyclization of 1-azapentadienyl anion was proposed.<sup>3)</sup> The dehydrogenation of **G** leading to **3** is much of interest, because another process, the deamination leading to **4**, seems to be a favorable one. Although a plausible explanation for the results is not found yet, we suggest that the substituted amino group at the 7-position might stabilize the 6*H*-pyrrolo[3,4-*d*]pyrimidine system.

In order to survey the usefulness of this method, the



Scheme 1.

Table 1. Reaction of 5-Formyl-6-(substituted amino)methyl-2,4(1*H*,3*H*)-pyrimidinediones **1** with Primary Amines **2**<sup>a)</sup>

<b>3</b>	<b>R<sup>1</sup></b>	<b>R<sup>2</sup></b>	<b>R<sup>3</sup></b>	<b>Yield/(%)<sup>b)</sup></b>	<b>4 Yield/(%)<sup>b)</sup></b>
<b>3a</b>	—	—	Ph	69	—
<b>3b</b>	—	—	Ph	59	—
<b>3c</b>	Et	Et	Ph	33	53
<b>3d</b>	Me	Ph	Ph	23	59
<b>3e</b>	—	—	C <sub>6</sub> H <sub>4</sub> -OMe( <i>p</i> )	65	—
<b>3f</b>	—	—	C <sub>6</sub> H <sub>4</sub> -Me( <i>p</i> )	66	—
<b>3g</b>	—	—	C <sub>6</sub> H <sub>4</sub> -Br( <i>p</i> )	64	—
<b>3h</b>	—	—	C <sub>6</sub> H <sub>4</sub> -Cl( <i>p</i> )	65	—
<b>3i</b>	—	—	1-Naphthyl	50	—
<b>3j</b>	—	—	Benzyl	32	—

a) In dry benzene under reflux for 2 d. b) Based on isolated products.

reaction of **1a** with arylamines and benzylamine were examined. In these reaction the 7-(substituted amino)-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-diones **3e–j** were obtained in good to fair yields. These results are summarized in Table 1.

Although much attention has been focused on the pharmacological potentialities of pyrrolo[3,4-*d*]pyrimidine derivatives, few reports on their preparation were found.<sup>3–5)</sup> We believe that our method based on the 1,5-cyclization of 5-anilinomethylene-5,6-dihydro-6-[(substituted amino)methylene]-2,4(1*H*,3*H*)-pyrimidinediones serves as a new entry into 7-(substituted amino)-6*H*-pyrrolo[3,4-*d*]pyrimidines.

### Experimental<sup>6)</sup>

The new starting materials **1b** and **1c** were prepared from the reaction of 5-formyl-1,3-dimethyl-6-bromomethyl-2,4(1*H*,3*H*)-pyrimidinedione and corresponding amines similarly to the reported method.<sup>3)</sup>

**5-Formyl-1,3-dimethyl-6-[(1-pyrrolidinyl)methyl]-2,4(1*H*,3*H*)-pyrimidinedione (**1b**):** Mp 123–125 °C. Found: C, 57.42; H, 7.00; N, 16.43%. Calcd for C<sub>12</sub>H<sub>17</sub>N<sub>3</sub>O<sub>3</sub>: C, 57.35; H, 6.82; N, 16.72%.

**6-[(Diethylamino)methyl]-5-formyl-1,3-dimethyl-2,4(1*H*,3*H*)-pyrimidinedione (**1c**):** 73–74 °C. Found: C, 57.14; H, 7.83; N, 16.64%. Calcd for C<sub>12</sub>H<sub>19</sub>N<sub>3</sub>O<sub>3</sub>: C, 56.90; H, 7.56; N, 16.59%.

**The Reaction of 1 with Aniline (2a). General Procedure:** The solution of **1c** (1 mmol) and aniline (**2a**) (1 mmol) in dry benzene (5 mL) was heated under reflux for 2 d, and the solvent was evaporated to dryness. The residue was subjected to column chromatography on silica gel to afford 109 mg (33%) of **3c** as elution of benzene/chloroform (1/1) to chloroform and 154 mg (53%) of **4** as elution of chloroform/ethyl acetate (4/1), respectively.

**1,3-Dimethyl-7-morpholino-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**3a**):** Colorless prisms (benzene-ethanol); mp 218–219 °C; IR (KBr) cm<sup>-1</sup>: 1690, 1640(CO); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ=2.8–3.0, 3.4–3.7 (4H, each, 2m, -CH<sub>2</sub>-), 3.40, 3.67 (3H, each, 2s, -CH<sub>3</sub>), 7.19 (3H, s, 5-H), 7.3–7.6 (8H, total, m and s, phenyl and benzene); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ=27.8, 31.5, 52.8, 67.0, 104.9 (4a-C), 118.2 (5-C), 120.8 (7a-C), 123.8 (7-C), 127.7, 128.3, 129.2 (benzene), 129.4, 139.3, 152.5 (2-C), 160.0 (4-C); MS *m/z*: 340 (M<sup>+</sup>). Found: C, 66.79; H, 6.07; N, 14.81%. Calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>3</sub>·1/2C<sub>6</sub>H<sub>6</sub>: C, 66.47; H, 6.12; N, 14.76%.

**1,3-Dimethyl-6-phenyl-7-(1-pyrrolidinyl)-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**3b**):** Colorless plates (hexane-ethanol); mp 226–227 °C; IR (KBr) cm<sup>-1</sup>: 1680, 1640

(CO); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ=1.6–1.8, 2.9–3.1 (4H, each, 2m, -CH<sub>2</sub>-), 3.41, 3.56 (3H, each, 2s, -CH<sub>3</sub>), 7.28 (1H, s, 5-H), 7.3–7.6 (5H, m, phenyl); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ=26.1, 27.8, 30.3, 53.4, 104.9, (4a-C), 117.2 (5-C), 120.2 (7a-C), 121.9 (7-C), 126.3, 128.5, 129.2, 139.0, 152.6 (2-C), 160.2 (4-C); MS *m/z*: 324 (M<sup>+</sup>). Found: C, 66.77; H, 6.20; N, 17.26%. Calcd for C<sub>18</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>: C, 66.65; H, 6.22; N, 17.27%.

**7-(Diethylamino)-1,3-dimethyl-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**3c**):** Pale yellow prisms (hexane-ethanol); mp 164–166 °C; IR (KBr) cm<sup>-1</sup>: 1690, 1650(CO); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ=0.96 (6H, t, -CH<sub>3</sub>, *J*=7 Hz), 2.88 (4H, q, -CH<sub>2</sub>-, *J*=7 Hz), 3.45, 3.68 (3H, each, 2s, -CH<sub>3</sub>), 7.29 (1H, s, 5-H), 7.3–7.6 (5H, m, phenyl); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ=13.5, 27.8, 31.1, 48.8, 104.8 (4a-C), 118.0 (5-C), 121.2 (7a-C), 122.5 (7-C), 127.0, 128.9, 129.1, 139.8, 152.7 (2-C), 160.3 (4-C); MS *m/z*: 326 (M<sup>+</sup>). Found: C, 66.40; H, 6.91; N, 17.34%. Calcd for C<sub>18</sub>H<sub>22</sub>N<sub>4</sub>O<sub>2</sub>: C, 66.24; H, 6.79; N, 17.16%.

**1,3-Dimethyl-7-(*N*-methylanilino)-6-phenyl-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**3d**):** Colorless prisms (hexane-ethanol); mp 168–170 °C; IR (KBr) cm<sup>-1</sup>: 1690, 1640(CO); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ=3.00, 3.28, 3.47 (3H, each, 3s, -CH<sub>3</sub>), 6.6–7.5 (10H, m, phenyl), 7.54 (1H, s, 5-H); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ=27.9, 30.2, 40.0, 105.5 (4a-C), 112.5 (5-C), 117.5 (7a-C), 122.2 (7-C), 118.0, 118.8, 125.2, 128.5, 129.4, 129.5, 137.8, 149.1, 152.3 (2-C), 159.9 (4-C); MS *m/z*: 360 (M<sup>+</sup>). Found: C, 70.31; H, 5.61; N, 15.62%. Calcd for C<sub>21</sub>H<sub>20</sub>N<sub>4</sub>O<sub>2</sub>: C, 69.98; H, 5.59; N, 15.55%.

**6-(*p*-Methoxyphenyl)-1,3-dimethyl-7-morpholino-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**3e**):** Pale yellow prisms (hexane-ethanol); mp 192–194 °C; IR (KBr) cm<sup>-1</sup>: 1690, 1650(CO); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ=2.9–3.2, 3.5–3.8 (4H, each, 2m, -CH<sub>2</sub>-), 3.50, 3.78, 3.99 (3H, each, 3s, -CH<sub>3</sub>), 7.13 (1H, s, 5-H), 7.2–7.5 (4H, m, phenyl); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ=27.8, 31.4, 52.8, 55.6, 67.0, 104.6 (4a-C), 114.3, 118.5 (5-C), 120.4 (7a-C), 124.0 (7-C), 128.8, 131.9, 152.5 (4-C), 160.0 (2-C), 160.2; MS *m/z*: 370 (M<sup>+</sup>). Found: C, 61.62; H, 5.81; N, 15.00%. Calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>4</sub>: C, 61.61; H, 5.99; N, 15.13%.

**1,3-Dimethyl-7-morpholino-6-(*p*-tolyl)-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**3f**):** Colorless plates (hexane-ethanol); mp 218–219 °C; IR (KBr) cm<sup>-1</sup>: 1690, 1650(CO); <sup>1</sup>H NMR (CDCl<sub>3</sub>) δ=2.48 (3H, s, -CH<sub>3</sub>), 2.8–3.2, 3.4–3.7 (4H, each, 2m, -CH<sub>2</sub>-), 3.44, 3.72 (3H, each, 2s, -CH<sub>3</sub>), 7.20 (1H, s, 5-H), 7.2–7.4 (4H, m, phenyl); <sup>13</sup>C NMR (CDCl<sub>3</sub>) δ=21.2, 27.8, 31.4, 52.8, 67.0, 104.7 (4a-C), 118.3 (5-C), 120.6 (7a-C), 123.8 (7-C), 127.4, 129.8, 136.8, 139.6, 152.5 (4-C), 160.0 (2-C); MS *m/z*: 354 (M<sup>+</sup>). Found: C, 64.26; H, 6.30; N, 15.69%. Calcd for C<sub>19</sub>H<sub>22</sub>N<sub>4</sub>O<sub>3</sub>: C, 64.39; H, 6.26; N, 15.81%.

**6-(*p*-Bromophenyl)-1,3-dimethyl-7-morpholino-6*H*-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (**3g**):** Pale yellow

prisms (hexane-ethanol); mp 207–209 °C; IR (KBr)  $\text{cm}^{-1}$ : 1700, 1650 (CO);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ =2.8–3.1, 3.4–3.7 (4H, each, 2m,  $-\text{CH}_2-$ ), 3.39, 3.66 (3H, each, 2s,  $-\text{CH}_3$ ), 7.16 (1H, s, 5-H), 7.2–7.3, 7.6–7.7 (2H each, 2m, phenyl);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$ =27.9, 31.7, 52.9, 67.0, 105.3 (4a-C), 118.0 (5-C), 121.0 (7a-C), 123.4, 123.6 (7-C), 129.2, 132.5, 138.3, 152.4 (4-C), 159.8 (2-C); MS  $m/z$ : 420, 418 ( $\text{M}^+$ ). Found: C, 51.64; H, 4.58; N, 13.16%. Calcd for  $\text{C}_{18}\text{H}_{19}\text{N}_4\text{O}_3\text{Br}$ : C, 51.56; H, 4.57; N, 13.36%.

**6-(*p*-Chlorophenyl)-1,3-dimethyl-7-morpholino-6H-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (3h):** Pale yellow prisms (hexane-ethanol); mp 206–208 °C; IR (KBr)  $\text{cm}^{-1}$ : 1700, 1650 (CO);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ =2.8–3.2, 3.3–3.8 (4H, each, 2m,  $-\text{CH}_2-$ ), 3.48, 3.75 (3H, each, 2s,  $-\text{CH}_3$ ), 7.30 (1H, s, 5-H), 7.4–7.7, 7.4–7.7 (4H, m, phenyl);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$ =27.9, 31.7, 52.8, 67.0, 105.3 (4a-C), 118.1 (5-C), 121.0 (7a-C), 123.7 (7-C), 128.9, 129.5, 135.5, 137.8, 152.4 (2-C), 159.9 (4-C); MS  $m/z$ : 376, 374 ( $\text{M}^+$ ). Found: C, 57.86; H, 5.13; N, 14.95%. Calcd for  $\text{C}_{18}\text{H}_{19}\text{N}_4\text{O}_3\text{Cl}$ : C, 57.68; H, 5.11; N, 14.95%.

**1,3-Dimethyl-7-morpholino-6-(1-naphthyl)-6H-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (3i):** Pale yellow plates (ethanol); mp 231–232 °C; IR (KBr)  $\text{cm}^{-1}$ : 1690, 1660 (CO);  $^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ =2.9–3.1, 3.2–3.5 (4H, each, 2m,  $-\text{CH}_2-$ ), 3.48, 3.74 (3H, each, 2s,  $-\text{CH}_3$ ), 7.30 (1H, s, 5-H), 7.4–8.2 (7H, m, aromatic);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$ =27.9, 31.5, 52.1, 53.0, 66.9, 67.0, 105.0 (4a-C), 119.3 (5-C), 120.4 (7a-C), 122.4, 124.9, 125.0 (7-C), 126.2, 127.1, 127.8, 128.3, 130.2, 131.5, 133.9, 135.8, 152.5 (2-C), 160.1 (4-C); MS  $m/z$ : 390 ( $\text{M}^+$ ). Found: C, 67.63; H, 5.68; N, 14.34%. Calcd for  $\text{C}_{22}\text{H}_{22}\text{N}_4\text{O}_3$ : C, 67.67; H, 5.68; N, 14.35%.

**6-Benzyl-1,3-dimethyl-7-morpholino-6H-pyrrolo[3,4-*d*]pyrimidine-2,4(1*H*,3*H*)-dione (3j):** Colorless plates (benzene-ethanol); mp 192–193 °C; IR (KBr)  $\text{cm}^{-1}$ : 1700, 1650 (CO);

$^1\text{H}$  NMR ( $\text{CDCl}_3$ )  $\delta$ =2.8–3.1, 3.5–3.8 (4H, each, 2m,  $-\text{CH}_2-$ ), 3.37, 3.60 (3H, each, 2s,  $-\text{CH}_3$ ), 5.17 (2H, s,  $-\text{CH}_2-$ ), 7.18 (1H, s, 5-H), 7.2–7.5 (5H, m, phenyl);  $^{13}\text{C}$  NMR ( $\text{CDCl}_3$ )  $\delta$ =27.8, 32.3, 51.2, 52.5, 67.3, 104.2 (4a-C), 117.3 (5-C), 121.5 (7a-C), 121.9 (7-C), 126.3, 128.1, 129.0, 136.8, 152.4 (2-C), 160.0 (4-C); MS  $m/z$ : 354 ( $\text{M}^+$ ). Found: C, 64.34; H, 6.30; N, 15.76%. Calcd for  $\text{C}_{19}\text{H}_{22}\text{N}_4\text{O}_3$ : C, 64.39; H, 6.26; N, 15.81%.

**1,3-Dimethyl-6-phenyl-6H-pyrrolo[3,4-*d*]pyrimidine-2,4-(1*H*,3*H*)-dione (4):** Colorless prisms (ethanol); mp 194–196 °C (lit.<sup>20</sup> 194–196 °C).

## References

- 1) Studies on Fused Pyrimidine Derivatives. Prat V. Part IV of this series: M. Noguchi, K. Sakamoto, S. Nagata, and S. Kajigaeshi, *Chem. Express*, to be submitted.
- 2) M. Noguchi, K. Sakamoto, S. Nagata, and S. Kajigaeshi, *J. Heterocycl. Chem.*, **25**, 205 (1988).
- 3) K. Hirota, Y. Yamada, T. Aso, and S. Senda, *Chem. Pharm. Bull.*, **29**, 1525 (1981).
- 4) For a review: V. Amarnath and R. Madhav, *Synthesis*, **1974**, 837.
- 5) T. Murata and K. Ukawa, *Chem. Pharm. Bull.*, **22**, 1212 (1974); G. Tarzia, G. Panzone, P. Carminati, P. Schiatti, and D. Selva, *Farmaco, Ed. Sci.*, **31**, 81 (1976); G. Tarzia, G. Panzone, *Gazz. Chim. Ital.*, **108**, 591 (1978); P. L. Southwick, R. Madhav, V. Amarnath, and T. Scheradsky, *Nucl. Acid Chem.*, **1**, 141 (1978); G. Tarzia, G. Panzone, P. Schiatti, and D. Selva, *Farmaco, Ed. Sci.*, **34**, 316 (1979); R. Madhav, C. A. Snyder, and P. L. Southwick, *J. Heterocycl. Chem.*, **17**, 1231 (1980).
- 6) The general experimental procedures were the same as in Part III.<sup>20</sup>